ResearchMoz

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease

GBI Research
Published Date » 2013-05-03
No. Of Pages » N/A
   
 GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.  
   
 The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Immunoglobulins Market to 2019 - Introduction
2.1 Overview

3 Immunoglobulins Market to 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost of Therapy
3.3 Immunoglobulins Market Drivers and Restraints
3.3.1 Market Drivers
3.3.2 Restraints

4 Immunoglobulins Market to 2019 - Geographical Landscape
4.1 US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy

5 Immunoglobulins Market to 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share for the Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-Barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Epidemiology
5.4.5 Current Use for Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/D
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% DIF
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-C
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 HyQvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy

7 Immunoglobulins Market to 2019 - Pipeline Analysis
7.1 Research and Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 IVIG3I Grifols 10%
7.2.2 RI-002 (IVIG)

8 Immunoglobulins Market to 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 CSL Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.A.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma AG
8.6.1 Business Description
8.6.2 Recent Developments

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape
9.1 M&A Deals
9.1.1 Grifols Buys 60% of Progenika Biopharma
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
9.2 R&D Licensing Agreements
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil

10 Immunoglobulins Market to 2019 - Asia-Pacific and China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute for Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling

11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
11.5 Contact Us
11.6 Disclaimer

List of Tables


Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2012-2019
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2012-2019
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2012-2019
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2012-2019
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2012-2019
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2012-2019
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2012-2019
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2012-2019
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2012-2019
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2012-2019
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2012-2019
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($),
2012-2019
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2012-2019
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication,
1994-2013
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013

List of Figures


Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2006-2019
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2006-2019
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2006-2019
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2006-2019
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2006-2019
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2006-2019
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011

Upcoming Reports:

Lime Flavored Soft Drinks Market - Global Industry Analysis, Size, Share, Trends Growth and Forecast, 2013 - 2019
By - Transparency Market Research
Lime flavored soft drinks market mainly comprises of companies that produce carbonated lemon drinks. Traditionally, lemon drinks made at home are not carbonated. Rising health issues due to consumption of cola and other drinks has led consumers to opt for non carbonated drinks such as lime flavored soft drinks. Lime flavored soft drinks are classified as, carbonated and non-carbonated. Over the past five years, carbonated lime flavored soft drinks have gained popularity along with other soft drink flavors owing to its refreshing property. The share of lime flavored drinks in overall...
Greece: market of scouring pastes and powders
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the scouring pastes and powders market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the scouring pastes and powders market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Contact Lenses Technologies Market- Global And China Forecast, Industry Share, Size, Growth And Industry Analysis (2010-2017)
By - Transparency Market Research
Contact Lenses are medical devices that are worn to improve vision. The major factors driving the contact lenses market are Aesthetics and Cosmetics. The eagerness to change the appearance of their eyes and overall personality is driving the contact lenses market globally. The research report analyses the industry growth rate, industry capacity, supply & demand side and industry structure. The report analyses the historical data and forecasts the contact lenses market size, production forecasts along with key factors driving and restraining the market....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Effective Liver Fat Detection Via Magnetic Resonance
Sep 18, 2014  
The issue of excess body weight has several adverse effects. Fat accumulation affects the internal organs as well, one of them being the liver. Hepatic Steatosis is a condition that causes fibrosis, cirrhosis, and inflammation due to fat deposits in the liver. Hitherto, hepatic biopsy has been the most popular technique for diagnosing hepatic fat. It is way more precise in determining the fat...
Philips App-enabled Devices for Pain Relief
Sep 18, 2014  
PulseRelief and Blue Touch are the two latest pain relief devices developed by Philips. These devices consist of app-enabled tools which are managed by iPads or iPhones.  These days a lot of importance is being given to pain management and not just exploring drug options for pain relief. Many suffer from chronic pain that after a point of time begins to affect their lifestyles,...
Effects of Refinery Project on Barrel Prices
Sep 18, 2014  
According to the electronic newsletter issued by the California Independent Petroleum Association on Monday, the refinery project poses major economic questions regarding bringing extra crude barrels into the California market. This will affect the local crude prices in the state.  The oil-by-rail project of Alon USA Energy Inc. on Rosedale Highway stirs several questions...
AWU to Bid Renewable Energy Target Reforms
Sep 17, 2014  
The Australian Workers Union has asked for exemptions for the aluminum industry from the Renewable Energy Target. This is speculated to place increased pressure on Labor to draw up a bipartisan deal with the Coalition regarding amendments to the scheme. Scott McDine, the national secretary for AWU has stated the Renewable Energy Target, if it progresses in its current state, would...
James White Drinks Introduces New Look in its Apple Juice Range
Sep 17, 2014  
James White Drinks – premium fruit and vegetable juice maker has introduced a new and fresh look to its Classics English Apple Juice range. The brand has launched the range in time for the Christmas market season which is due in a few months.  Sourced from the English orchards featuring a richly-fine taste as perfect as a non-alcoholic alternative to wine products, this has...